Newer Management Protocols for Celiac Disease

Introduction And Rationale

Management protocols have shifted from basic symptom resolution to proactive, multidisciplinary care emphasizing structured follow-up, adherence assessment, nutritional optimization, and quality of life.
These updates aim to prevent long-term complications, including osteoporosis, malignancy, and infertility, while addressing specific pediatric challenges like catch-up growth and school integration.
Clinical care is governed by the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) 2022 guidelines (endorsed 2025–2026), the 2024 Gluten-Free Diet (GFD) Position Paper, and the NASPGHAN 2025 guidelines.

ESPGHAN and NASPGHAN mandate proactive monitoring to ensure mucosal healing and adherence.

Parameter	Clinical Recommendation
Visit Timing	First follow-up scheduled at 3 to 6 months post-diagnosis; subsequent visits occur annually if the patient remains stable.
Serological Monitoring	Serial tracking of TGA-IgA (or IgG in IgA-deficient cases); persistent TGA elevation exceeding 10 times the upper limit of normal strictly mandates a repeat biopsy.
Nutritional Evaluation	Routine assessment of growth, complete blood count, ferritin, folate, and vitamin levels.
Adherence Tracking	Evaluated via dietitian interviews and validated questionnaires rather than subjective clinical impression.

A strict, lifelong GFD remains the foundational cornerstone of therapy.
The 2024 GFD Position Paper explicitly defines safe GFD thresholds as strictly below 20 ppm of gluten.
Protocols emphasize pediatric-specific education regarding cross-contamination and food labeling compliance.
Indian Council of Medical Research (ICMR) guidelines prioritize integrating dietitian counseling and community patient support groups to improve adherence in resource-limited settings.

NASPGHAN protocols emphasize routine screening in at-risk pediatric populations, specifically children with Type 1 Diabetes, Down syndrome, short stature, and a positive family history.

Asymptomatic children classified with "potential celiac disease" remain on a gluten-containing diet.
They require annual clinical and serological monitoring, as approximately 13% will progress to overt celiac disease within 18 months.

Transition to adult gastroenterology care requires a structured "celiac passport".
This document contains a comprehensive diagnosis summary, historical serology trends, and records of any associated comorbidities.

Tissue Transglutaminase (TG2) Inhibitors: Phase 2/3 trial data (2026) for ZED1227 demonstrates significant mucosal protection and systemic multiomic reversal during acute gluten challenges.
Microbiome And Immune-Modulators: Agents like amlitelimab and ritlecitinib are currently in Phase 2 clinical trials targeting non-responsive celiac disease.
Digital Health Interventions: NASPGHAN highlights the integration of Artificial Intelligence diagnostics and behavioral telehealth frameworks (e.g., the GROW Program) to enhance adherence and quality of life.